GLP-1 coverage for PCOS: the policies that count it at BMI 27

No GLP-1 carries an FDA indication for PCOS, and none of the policies we hold covers one on a PCOS diagnosis alone. Coverage runs through the obesity pathway instead. Four of the five policies below list polycystic ovary syndrome as a weight-related condition, which moves the requirement from BMI 30 to BMI 27. The fifth, Highmark, lists PCOS but sets its own floor at BMI 40.

Why a PCOS diagnosis alone does not get a GLP-1 covered

Between them, Wegovy and Zepbound are labeled for chronic weight management, cardiovascular risk, sleep apnea and liver disease. Neither label names PCOS.

A prior authorization filed with PCOS as the indication asks a plan to cover a use no label carries. The letter templates below list that as a denial trigger.

The lists differ by payer and by employer

Cigna reads both the BMI and the condition at baseline, meaning before any GLP-1 or GLP-1/GIP agonist. Highmark wants two conditions from its list and a baseline BMI of 40. Kaiser's Northwest and Mid-Atlantic regions publish different lists from each other. Our payer coverage pages carry each policy document, its number and the date we read it, so you can take the exact wording to your prescriber.

Two of our prior-authorization letter templates cover PCOS with metabolic syndrome: CareFirst BCBS and Florida Blue. Both file PCOS as the qualifying condition under the obesity or type 2 diabetes pathway, and both cite the policy the plan published.

If the plan says no

Every policy on this page requires prior authorization, and several plans exclude weight-loss drugs at the employer level. Where that happens the cash price is the fallback. The price chart shows what every US telehealth program charges a month, all in, checked every Monday. Our insurance guide covers how the appeal is filed.

This is coverage information, not medical advice.